FY2018 Earnings Estimate for Charles River Laboratories International, Inc. Issued By SunTrust Banks (CRL)

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at SunTrust Banks dropped their FY2018 EPS estimates for shares of Charles River Laboratories International in a note issued to investors on Thursday. SunTrust Banks analyst S. Draper now expects that the medical research company will post earnings of $5.68 per share for the year, down from their previous forecast of $5.73. SunTrust Banks has a “Buy” rating and a $113.00 price target on the stock.

Other analysts have also issued research reports about the stock. Jefferies Group LLC boosted their price objective on shares of Charles River Laboratories International from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. Bank of America Corporation lowered their target price on shares of Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, November 10th. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 target price on the stock in a report on Tuesday, October 24th. Robert W. Baird restated a “buy” rating and set a $114.00 target price on shares of Charles River Laboratories International in a report on Friday, September 1st. Finally, BidaskClub downgraded shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Charles River Laboratories International currently has an average rating of “Buy” and an average target price of $106.63.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/11/21/fy2018-earnings-estimate-for-charles-river-laboratories-international-inc-issued-by-suntrust-banks-crl.html.

Shares of Charles River Laboratories International (NYSE CRL) traded up $0.92 during mid-day trading on Monday, hitting $102.43. 364,263 shares of the stock were exchanged, compared to its average volume of 381,296. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88. The company has a market capitalization of $4,800.00, a price-to-earnings ratio of 19.92, a PEG ratio of 1.62 and a beta of 0.94. Charles River Laboratories International has a twelve month low of $69.51 and a twelve month high of $119.05.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Thursday, November 9th. The medical research company reported $1.30 EPS for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.08. The business had revenue of $464.23 million for the quarter, compared to analyst estimates of $458.93 million. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.18 earnings per share.

Several hedge funds have recently made changes to their positions in the company. Public Employees Retirement System of Ohio grew its position in shares of Charles River Laboratories International by 83.6% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 41,086 shares of the medical research company’s stock worth $4,438,000 after buying an additional 18,703 shares during the period. GSA Capital Partners LLP grew its position in shares of Charles River Laboratories International by 83.4% during the 3rd quarter. GSA Capital Partners LLP now owns 23,184 shares of the medical research company’s stock worth $2,504,000 after buying an additional 10,544 shares during the period. Ameritas Investment Partners Inc. grew its position in shares of Charles River Laboratories International by 56.1% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 22,256 shares of the medical research company’s stock worth $2,415,000 after buying an additional 8,000 shares during the period. California Public Employees Retirement System grew its position in shares of Charles River Laboratories International by 14.8% during the 3rd quarter. California Public Employees Retirement System now owns 78,155 shares of the medical research company’s stock worth $8,442,000 after buying an additional 10,055 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of Charles River Laboratories International during the 3rd quarter worth approximately $694,000. 98.72% of the stock is owned by institutional investors.

In other news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $0.27, for a total transaction of $270,000.00. Also, insider Davide Molho sold 5,982 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $107.55, for a total transaction of $643,364.10. Following the sale, the insider now directly owns 22,714 shares of the company’s stock, valued at approximately $2,442,890.70. The disclosure for this sale can be found here. In the last three months, insiders bought 10,500 shares of company stock valued at $2,885 and sold 1,012,147 shares valued at $1,591,514. Insiders own 2.20% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply